ClinicalTrials.gg
CompletedNCT05882695Updated Jun 29, 2025

Study of SPG302 in Healthy Volunteers and ALS Participants

A Phase 1 interventional study of SPG302 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Spinogenix. Completed at 4 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Spinogenix · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Enrollment
18th of 44
88 · median 63
Started
2023
with 1 other
Phase 1
5 of 44
2 open now
Registered
32nd of 44
by date
Lead sponsor
2 of 44
Spinogenix

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 18th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 1, and was the 32nd registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants

Read the detailed description

This study is a Phase 1 randomized, double-blind, placebo-controlled, single, and multiple ascending dose study in HV with food effect cohort, and a repeat dose expansion cohort(s) in participants with ALS.

The study consists of 3 parts, as follows:

  • Part 1: SAD in HV with up to 6 cohorts including a food effect cohort.
  • Part 2: MAD over 5 days in HV with up to 5 cohorts
  • Part 3: ALS cohorts with once daily (QD) dosing over 28 day cycles
03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic Lateral Sclerosis
  • regenerative
  • synapse
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-55
  • Must be in good health with no significant medical history
  • Clinical laboratory values within normal range or \< 1.2 times
  • 18-32 (inclusive)
  • use by men or women consistent with local regulations
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Any physical or psychological condition that prohibits study completion
  • Known cardiac disease
  • Active or history of in the past 5 years
  • Serious infection within 1 month of screening
  • Acute illness within 30 days of Day 1
  • Surgery, bone fracture, or major musculoskeletal injury in the past 3 months
  • History of suicidal behavior or suicidal ideation
  • Active cigarette smokers and users of nicotine-containing products
  • , and positive
  • SBP >140 or \<90
  • DBP >90 or \<40
  • HR \<40 or >100
  • >450ms, cardiac arrhythmia, or abnormal
  • Prescriptions, over-the-counter, or herbal medication within 7 days
  • Vaccines within 14 days
  • Other products within 30 days
  • Blood donation within 30 days
  • Plasma donation within 7 days
  • Pregnant or breastfeeding
  • Otherwise unfit, on metabolic-altering lifestyle/diet, positive urine drug screen or intake of alcohol or caffeine-containing products

ALS Cohort Inclusion Criteria:

  • Age 18-80
  • ALS TRICALS risk score
  • Stable dose of standard of care treatment
  • use by men or women consistent with local regulations
  • Able and willing to provide written

ALS Cohort Exclusion Criteria:

  • Underlying physical or psychological condition prohibiting study completion
  • Known cardiac disease
  • Active or history of malignancy in the past 5 years
  • Serious infection within 1 month of screening
  • Acute illness within 30 days of Day 1
  • History of suicidal behavior or suicidal ideation
  • Active cigarette smokers and users of nicotine-containing products
  • Neurodegenerative disease
  • External respiratory support or supplemental oxygen requirement
  • HIV, hepatitis B and hepatitis C positive
  • SBP >140 or \<90
  • DBP >90 or \<40
  • HR \<40 or >100
  • QTcF >450ms, cardiac arrhythmia, or clinically significant abnormal ECG
  • Vaccines within 14 days
  • Other investigational products within 30 days
  • Blood donation within 30 days
  • Plasma donation within 7 days
  • Pregnant or breastfeeding
  • Otherwise unfit
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Experimental Part 1: Active SPG302 to be administered to healthy volunteers (SAD)

    8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule

    Drug: SPG302

  • Placebo comparator
    Placebo Comparator Part 1: Placebo comparator to be administered to healthy volunteers (SAD)

    8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule

    Drug: Placebo

  • Experimental
    Experimental Part 2: Active SPG302 to be administered to healthy volunteers (MAD)

    8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).

    Drug: SPG302

  • Placebo comparator
    Placebo Comparator Part 2: Placebo comparator to be administered to healthy volunteers (MAD)

    8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).

    Drug: Placebo

  • Experimental
    Experimental Part 3: Active SPG302 to be administered to participants with ALS

    Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.

    Drug: SPG302

  • Placebo comparator
    Placebo Comparator Part 3: Placebo comparator to be administered to participants with ALS

    Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.

    Drug: Placebo

  • Experimental
    Experimental Part 3: Open Label Extension - Active SPG302 administered to participants with ALS

    Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days for up to 3 cycles in the USA and up to 12 cycles in Australia. A follow-up safety visit will be conducted 30 days after last dose (±7 days).

    Drug: SPG302

Interventions

  • DrugSPG302

    synthetic small molecule

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability in healthy volunteers (SAD cohort)

    • Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 7 days

  2. Safety and tolerability in healthy volunteers (SAD food effect cohort)

    • Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 15 days

  3. Safety and tolerability in healthy volunteers (MAD cohort)

    • Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 12 days

  4. Safety and tolerability in participants with ALS

    • Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 60 days

Secondary outcomes

  1. Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD cohort)

    PK parameters of SPG302 on concentrations in plasma

    Time frame: 7 days

  2. Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD food effect cohort)

    Effects of food on SPG302 PK profile

    Time frame: 15 days

  3. Plasma pharmacokinetics of SPG302 in healthy volunteers (MAD cohort)

    PK parameters of SPG302 on concentrations in plasma

    Time frame: 12 days

  4. Plasma pharmacokinetics of SPG302 in participants with ALS

    PK parameters of SPG302 on concentrations in plasma

    Time frame: 12mon

  5. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    Spirometry

    Time frame: 12 mon

  6. Clinical efficacy measures of SPG302 in participants with ALS

    The Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R).

    Time frame: 12 mon

Other outcomes

  1. Effect of repeated dosing of SPG302 on electroencephalogram in healthy volunteers (MAD cohort)

    Change from baseline in EEG parameters

    Time frame: 12 mon

  2. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    Number of respiratory complications

    Time frame: 12 mon

  3. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    Spirometry

    Time frame: 12 mon

  4. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    TMS

    Time frame: 12 mon

  5. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    EEG

    Time frame: 12 mon

  6. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    Change in Nocturnal Pulse Oximetry

    Time frame: 12 mon

  7. Clinical outcomes of multiple oral doses of SPG302 in participants with ALS

    Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

    Time frame: 12mon

  8. Effect of SPG302 on proteins and biomarkers in participants with ALS

    Multiple protein and immunological biomarkers

    Time frame: 12mon

  9. The effect of SPG302 on protein(s) and biomarkers

    Change from baseline in the analysis of Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: 12mon

07

Study locations

4 sites
  • Macquarie University
    North Ryde, New South Wales 2109, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Flinders Medical center
    Adelaide, South Australia 5042, Australia
  • Nucleus Melbourne (healthy volunteers)
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2025, 23 months.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 23 months is close to that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
May 31, 2023
StartActual
Jul 3, 2023
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05882695
Lead sponsor
Spinogenix
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jul 3, 2023
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Last update
Jun 29, 2025

Study contacts

Ofer M Gonen, MD
principal investigator · Nucleus Network (for healthy volunteers)
David Schultz (ALS site), MD
principal investigator · Finders Medical Center (ALS)
Robert Henderson (ALS site), MD
principal investigator · Royal Brisbane Hospital (ALS)
Dominic Rowe, MD
principal investigator · Macquarie Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPG-302

Start the discussion